about
Chemerin and adiponectin contribute reciprocally to metabolic syndromePharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects.Comparison of Pharmacokinetics and Safety of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects.Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?Compartmental inhibition of hepatic glutathione reductase activities by 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) in Sprague-Dawley and Fischer-344 rats.Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation.Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates?Lung development alterations in newborn mice after recovery from exposure to sublethal hyperoxia.Altered expressions of fibroblast growth factor receptors and alveolarization in neonatal mice exposed to 85% oxygen.Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteersGenitopatellar Syndrome Secondary to Mutation: The First Genetically Confirmed Case in South KoreaInfluence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartanInfluence of hepatic dysfunction on the pharmacokinetics and safety of fimasartanFirst-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjectsCoagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult SubjectsDecreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysisSignal Detection of Adverse Events Following Pneumococcal Vaccines from the Korea Adverse Event Reporting System Database, 2005-2016Implementation of a Targeted Next-Generation Sequencing Panel for Constitutional Newborn Screening in High-Risk NeonatesEvaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
P50
Q28730639-CEE38E05-0DA6-4FB2-81AE-3DC408BE53EAQ37426862-6902ECB5-1A1D-4236-9213-36EECEC4C810Q38372286-35D0F098-38C8-4DFA-A856-277D1CC2079EQ38374584-F0FFA5C0-884D-4223-B54A-E0164686A9FCQ38408260-D22F85CF-8103-45A8-827C-A4E4A46DFB27Q38426511-0548DE0E-1AAA-4166-A364-49A858363813Q42012894-038C953C-621A-4557-978E-AC5493801441Q44855591-2B988157-EEC7-490A-BE68-9165C06E2FADQ47152342-70E637A6-7F9D-4574-B516-CBD04D029075Q47292635-FCB5E730-8914-4CEA-A9BE-BA006199508EQ50689147-5DEAC54D-52C4-43F0-A9C6-049D0DB1872FQ51974340-847019A1-BBDF-45A4-8DBA-1B47DAEA99F8Q58806308-E74DC4D0-E631-4EF8-B4FC-059888D2FF69Q64078229-5C7F7BB2-83EF-4AD0-8F07-FAE0CEAF9A90Q83863162-C0808B0E-50E2-4EBC-B625-080F0223F784Q86422667-1C5ADC49-CEC2-442E-9860-8208AE4342E5Q87066017-251C9531-1115-41A0-AF0E-98F6E8968FD8Q89440753-ECB68680-C8D3-4708-AAC7-796863006D09Q89869274-CCA272B7-6660-4CBB-B8FA-C7AF9417EFF1Q89894830-38C608CB-DA7D-420D-AC6D-140828EE9A00Q90867376-FF866F0E-1E88-46B0-9C5F-96094D90542EQ91795572-04516E5B-5473-4252-8606-A3E478C3AA2B
P50
description
researcher ORCID ID = 0000-0002-4395-9938
@en
wetenschapper
@nl
name
Min Soo Park
@ast
Min Soo Park
@en
Min Soo Park
@es
Min Soo Park
@nl
type
label
Min Soo Park
@ast
Min Soo Park
@en
Min Soo Park
@es
Min Soo Park
@nl
prefLabel
Min Soo Park
@ast
Min Soo Park
@en
Min Soo Park
@es
Min Soo Park
@nl
P1153
35730633000
57196374082
P31
P496
0000-0002-4395-9938